- Home
- INCY vs BCH Comparison
INCY vs BCH Comparison
Compare INCY & BCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BCH
- Stock Information
- Founded
- INCY 1991
- BCH 1893
- Country
- INCY United States
- BCH Chile
- Employees
- INCY N/A
- BCH N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BCH Commercial Banks
- Sector
- INCY Health Care
- BCH Finance
- Exchange
- INCY Nasdaq
- BCH Nasdaq
- Market Cap
- INCY 13.4B
- BCH 13.1B
- IPO Year
- INCY 1993
- BCH 2002
- Fundamental
- Price
- INCY $58.21
- BCH $27.97
- Analyst Decision
- INCY Hold
- BCH Hold
- Analyst Count
- INCY 20
- BCH 1
- Target Price
- INCY $74.00
- BCH $23.00
- AVG Volume (30 Days)
- INCY 2.3M
- BCH 392.9K
- Earning Date
- INCY 04-29-2025
- BCH 04-29-2025
- Dividend Yield
- INCY N/A
- BCH 7.48%
- EPS Growth
- INCY N/A
- BCH N/A
- EPS
- INCY 0.15
- BCH 0.01
- Revenue
- INCY $4,241,216,999.00
- BCH $2,816,160,332.00
- Revenue This Year
- INCY $12.21
- BCH $18.71
- Revenue Next Year
- INCY $9.20
- BCH $5.56
- P/E Ratio
- INCY $345.39
- BCH $10.92
- Revenue Growth
- INCY 14.76
- BCH N/A
- 52 Week Low
- INCY $50.35
- BCH $21.37
- 52 Week High
- INCY $83.95
- BCH $28.64
- Technical
- Relative Strength Index (RSI)
- INCY 40.69
- BCH 60.19
- Support Level
- INCY $57.05
- BCH $23.66
- Resistance Level
- INCY $59.95
- BCH $27.40
- Average True Range (ATR)
- INCY 2.76
- BCH 0.87
- MACD
- INCY 0.18
- BCH 0.19
- Stochastic Oscillator
- INCY 46.45
- BCH 94.73
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.